MONICA
CABRERO CALVO
Investigadora Predoctoral
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (7)
2017
-
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
American Journal of Hematology, Vol. 92, Núm. 4, pp. 351-358
2016
-
Down-regulation of EZH2 expression in myelodysplastic syndromes
Leukemia Research, Vol. 44, pp. 1-7
-
Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion
British Journal of Haematology
-
PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Clinical Lymphoma, Myeloma and Leukemia, Vol. 16, pp. S67-S73
2015
-
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes
Clinical Cancer Research, Vol. 21, Núm. 5, pp. 985-994
-
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes
Leukemia Research, Vol. 39, Núm. 12, pp. 1367-1374
-
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up
Leukemia Research, Vol. 39, Núm. 5, pp. 520-524